|Day Low/High||12.70 / 13.55|
|52 Wk Low/High||7.75 / 37.20|
In recent trading, shares of Impax Laboratories Inc have crossed above the average analyst 12-month target price of $12.00, changing hands for $12.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,670,394 share decrease in total short interest for Impax Laboratories Inc , to 3,500,878, a decrease of 32.30% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.
Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.
Industry Veteran Brings a Successful Record of Operational Execution, Driving Transformation and Delivering Growth
Investors in Impax Laboratories Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IPXL options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.
The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.
Investors in Impax Laboratories Inc saw new options become available this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
The drug maker's shares have fallen 6.2% since Wednesday's market open.
The price of EpiPens has surged about 25% annually since 2007.
Health insurance giant Cigna said it will no longer cover Mylan's EpiPen.
Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?
Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Glancy Prongay & Murray LLP ("GPM") reminds investors of the January 9, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased Impax...